

Pfizer Announces an Independent Medical Education Grant RFP

Improvement of Treatment Environment for Advanced / Recurrent Breast Cancer

日本語版はこちらをクリックしてください↓

Note this RFP is also available in Japanese for your convenience

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all **independent medical education grants**, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

October2021





II. Eligibility

Geographic Scope:	Japan
Applicant Eligibility Criteria	The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project.

III. Requirements

Date RFP Issued	February 8, 2022
Clinical Area	Breast Cancer
General Area of Interest for this RFP:	In recent years, treatment options for advanced / recurrent breast cancer have expanded rapidly, and the overall prognosis for life has been improving, but on the other hand, new challenges have arisen due to the diversification of therapeutic agents and the long treatment period. Therefore, the role of comedical staff in treatment and patient care of breast cancer area is becoming more important ¹⁻⁴⁾ .
	An educational grant program will be offered to promote the improvement of disease domain knowledge and comprehensive patient care skills of comedical staff such as pharmacists and nurses in the area of advanced / recurrent breast cancer.
	This competitive grant is an educational program that addresses the following issues, but it is not limited to these issues.
	 Minimize disparities across institutions (ie. urban/rural or academic/community) in cancer-related expertise, treatment, and care environment for co-medical staff such as pharmacists and nurses, involved in the care of patients with advanced/recurrent breast cancer.
	Improve medical communication between medical professional and patients with advanced / recurrent breast cancer with a focus toward improving environment for shared decision making
	leverage multidisciplinary collaboration among team medical care to





	provide holistic support to patients with advanced/recurrent breast cancer
	 Improve the knowledge of co-medical staff involved in the management of side effects associated with treatments such as molecular targeted drug therapy and chemotherapy.
	The format of the educational program can be events, satellite symposiums, workshops, online courses (content), printed matter, etc.
	It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. In addition, it is not also our intent to support guideline development (e.g., clinical treatment guidelines) from the viewpoint of COI.
Target Audience:	Nurses, pharmacists, and other co-medical staff who involved in the treatment and care of breast cancer patients
Expected Approximate Monetary Range of Grant Applications:	Individual projects requesting up to 10,000,000 JPY will be considered. The estimated total available budget related to this RFP is 20,000,000 JPY.
Key Dates:	RFP release date: February 8, 2022
	Grant Application due date: March 29, 2022
	Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
	Anticipated Grant Award Notification Date: June 2022
	 Grants will be distributed following a fully executed agreement.
	Anticipated Project Start and End Dates: September 1, 2022 - October 31, 2024
How to Submit:	Please go to www.cybergrants.com/pls/cybergrants/
Thew to cubinit.	and sign in. First-time users should click "Create your password".
	 For the question "Are you replying to a Request for Proposal as part of the Competitive Grant Program?" select Yes Select the following Competitive Grant Program Name: "2022 ONC JP: Improvement of Treatment Environment for Advanced / Recurrent BC" Select the following Primary Area of Interest: "Oncology - Breast" Requirements for submission: Complete all required sections of the online application and upload your project proposal (see Appendix) in Independent Medical Education RFP Submission field.





	If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page. IMPORTANT: Be advised applications submitted after the due date will not be reviewed by the committee.
Questions:	MEG-J Office, Pfizer Japan Inc.
	meg.japan@pfizer.com Please include the title of this open call, " Improvement of Treatment Environment for Advanced / Recurrent Breast Cancer," in the subject line of your e-mail.
Grant Agreements:	If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.
	Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
Review and Approval Process:	Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
Mechanism by which Applicants will be Notified:	All applicants will be notified via email by the dates noted above. Applicants may be asked for additional clarification during the review period. Pfizer must complete payment procedure by the end of November 2022. Please confirm the procedure of your institution for receiving our grant before
	proceeding with submission of your application.





Reference

- 1) Journal of Japanese Society of Cancer Nursing (0914-6423)18(2): 62-68(2004.12)
- 2) Japanese Journal of Cancer and Chemotherapy (0385-0684)47(8): 1209-1212(2020.08)
- 3) Journal of Pharmaceutical Health Care and Sciences (2055-0294)4 April: 1-14(2018.04)
- 4) Journal of Japanese Society of Hospital Pharmacists (1341-8815)44(4): 593-596(2008.04)





Appendix A

General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

Goals and Objectives	 Briefly state the overall goal of the project. List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
Needs Assessment for the Project	 Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
Target Audience	 Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
Project Design and Methods	 Describe the planned project, the educational approach, and the way the planned methods address the established need.
Innovation	 Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.
Evaluation and Outcomes	• In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.
Dissemination Plan	Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
Anticipated Project Timeline	 Provide an anticipated timeline for your project including project start/end dates





Additional Information	 If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
Organization Detail	 Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.
Budget Narrative	 Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application
	While estimating your budget please keep the following items in mind:
	 Independent Medical Education Grants awarded by Pfizer cannot be used to purchase therapeutic assets (prescription or non- prescription).
	 Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.



